Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-0941 DFC · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| DFC (fasted) | EXPERIMENTAL | - |
| OCT (fasted) | EXPERIMENTAL | - |
| OCT (after meal) | EXPERIMENTAL | - |
| OCT (before meal) | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| 10 mg MK-0941 DFC (fasted) | DRUG | single dose of 10 mg MK-0941 dry filled capsules (DFC) administered in a fasted state |
| 10 mg MK-0941 OCT (after meal) | DRUG | single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered after consumption of a high-fat meal |
| 10 mg MK-0941 OCT (before meal) | DRUG | single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered before consumption of a standard breakfast |
| 10 mg MK-0941 OCT (fasted) | DRUG | single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered in a fasted state |
Inclusion Criteria: * Males or females (of non-childbearing potential) between the ages of 18 to 70 * Participants have been diagnosed with Type 2 Diabetes * Participants are nonsmokers for at least 6 months Exclusion Criteria: * Participant should not be diagnosed with Type 1 diabetes * Particip...
MK-0941 DFC is an investigational small molecule being studied for the treatment of Type 2 Diabetes Mellitus. It is a glucokinase activator developed by Merck & Company, Inc. (MRK) and has been evaluated in a Phase 1 clinical trial. It is not approved for any indication.
MK-0941 DFC targets glucokinase (GCK), an enzyme that plays a key role in glucose metabolism. It acts as a glucokinase activator, meaning it enhances the activity of GCK. This mechanism is being investigated for its potential to lower blood glucose in people with Type 2 Diabetes Mellitus.
MK-0941 DFC is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. Merck is the sponsor of the clinical program evaluating this glucokinase activator for Type 2 Diabetes Mellitus.
MK-0941 DFC is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any regulatory agency. The Phase 1 program includes one completed trial with 18 participants.
MK-0941 DFC has been studied in one completed Phase 1 trial, NCT00567112, titled "Study to Evaluate the Pharmacokinetics & Food Effect of MK-0941 in Adults With Type 2 Diabetes (MK-0941-009)." The trial enrolled 18 adults with Type 2 Diabetes Mellitus and was active-controlled and randomized.